Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673423 | 0.90 | PIK3CD (0.43) | PIK3CDPIK3CAHDAC1PIK3CG | |
| SCHEMBL2112274 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3CAHDAC1PIK3CG | |
| SCHEMBL2101166 | 0.83 | PIK3CD (0.45) | PIK3CDPIK3CAHDAC1PIK3CG | |
| SCHEMBL2394854 | 0.83 | PIK3CD (0.53) | PIK3CDPIK3CAHDAC1CYP3A4 | |
| SCHEMBL2398263 | 0.83 | PIK3CD (0.63) | PIK3CDPIK3CAHDAC1PIK3CG | |
| SCHEMBL2394343 | 0.81 | HDAC1 (0.39) | PIK3CDHDAC1PIK3CG | |
| SCHEMBL2396138 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3CAHDAC1CYP3A4 | |
| SCHEMBL9936995 | 0.80 | HDAC1 (0.40) | PIK3CDHDAC1CYP3A4 | |
| SCHEMBL30471263 | 0.80 | HDAC1 (0.40) | PIK3CDHDAC1CYP3A4 | |
| SCHEMBL9937266 | 0.78 | HDAC1 (0.37) | PIK3CDPIK3CAHDAC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885PIK3CA 1/4885HDAC1 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.